News
DMAC
3.690
+1.10%
0.040
Weekly Report: what happened at DMAC last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at DMAC last week (0708-0712)?
Weekly Report · 07/15 09:47
DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point
DM199 for the treatment of patients with acute ischemic stroke is expected to be worth $14 billion by 2032. The drug could act as a disease-modifying therapy for these patients. DM199 is also being explored in a phase 2 study for women with pregnancy complications. DiaMedica Therapeutics expected to complete enrollment for an interim futility analysis of its AIS trial by early 2025.
Seeking Alpha · 07/11 18:48
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
DiaMedica Therapeutics Inc. Will host a virtual key opinion leader webinar on July 29, 2024. The webinar will focus on the expansion of its clinical development program for DM199 into preeclampsia, a life-threatening pregnancy associated vascular disorder with no FDA-approved treatment. DM199 has the potential to lower blood pressure and improve fetal growth restriction.
Barchart · 07/11 07:00
DiaMedica Therapeutics files to sell 4.72M common shares for holders
Seeking Alpha · 07/10 20:28
DiaMedica Therapeutics Files For Resale Of Up To 4.7M Common Shares By The Selling Shareholders
Benzinga · 07/10 20:26
DIAMEDICA THERAPEUTICS INC FILES FOR RESALE OF UP TO 4.7 MLN COMMON SHARES BY THE SELLING SHAREHOLDERS - SEC FILING
Reuters · 07/10 20:17
Diamedica Therapeutics (DMAC) Gets a Buy from Craig-Hallum
TipRanks · 07/08 13:15
Weekly Report: what happened at DMAC last week (0701-0705)?
Weekly Report · 07/08 09:47
DiaMedica Completes $11.8Mln Private Placement
NASDAQ · 07/02 11:35
DIAMEDICA THERAPEUTICS ANNOUNCES CLOSING OF $11.8 MILLION PRIVATE PLACEMENT
Reuters · 07/01 12:00
Weekly Report: what happened at DMAC last week (0624-0628)?
Weekly Report · 07/01 09:47
Diamedica Therapeutics (DMAC) Receives a Buy from Craig-Hallum
TipRanks · 06/27 12:56
DiaMedica Therapeutics Shares Rise 12% After $12M Private Placement
Dow Jones · 06/26 14:10
Lake Street Remains a Buy on Diamedica Therapeutics (DMAC)
TipRanks · 06/26 12:56
Diamedica Therapeutics Expands Trials to Address Preeclampsia
TipRanks · 06/26 12:32
DiaMedica Therapeutics looks to raise $11.8M through private placement
Seeking Alpha · 06/26 12:27
DiaMedica Therapeutics Announces $11.8M Private Placement, Will Issue A Total Of 4.72M Common Shares At A Purchase Price Of $2.50 Per Share
DiaMedica Therapeutics Inc. Is a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases. The company has entered into agreements to sell its common shares in a private placement. The transaction is expected to result in gross proceeds of $11.8 million.
Benzinga · 06/26 12:17
DIAMEDICA: WILL ISSUE 4.72 MLN SHARES AT $2.50/SHARE
Reuters · 06/26 12:15
DiaMedica Therapeutics Announces Expansion Of DM199 Program Into Preeclampsia
Preeclampsia is a life-threatening pregnancy-associated vascular disorder. There are no approved drugs for preeclampsy in the U.S. Or Europe. DiaMedica Therapeutics Inc. Plans to begin a Phase 2 Investigator-sponsored trial in Q4 2024.
Benzinga · 06/26 12:01
More
Webull provides a variety of real-time DMAC stock news. You can receive the latest news about Diamedica Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.